Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study #UCOPapers 👨🏽🔬 @IMIBIC 📖 BioMed Central https://t.co/W1E0lHBZnq
Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted [..] https://t.co/JkWZSeKgxX Included at COVID-19 & Spain #MeedCOVID19 https://t.co/HJyKalLaLq @BMCMedicine @BioMedCentral @SEDiabetes @semfyc @CIBER_OBN @_i
Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study | BMC Medicine @Sociedad_SEMI @RGomezHuelgas @Diabetes_SEMI https://t.co/vIN6L
RT @BMCMedicine: New #openaccess research from Luis Pérez-Belmonte and co: #Mortality and other adverse outcomes in patients with type 2 #d…
A propensity for the truth “Use of glucose-lowering drugs prior to admission showed no significant association with mortality and adverse outcomes #COVID19 “ #T2D #diabetes @BMCMedicine https://t.co/qVDYb0hQFl
RT @BMCMedicine: New #openaccess research from Luis Pérez-Belmonte and co: #Mortality and other adverse outcomes in patients with type 2 #d…
New #openaccess research from Luis Pérez-Belmonte and co: #Mortality and other adverse outcomes in patients with type 2 #diabetes mellitus admitted for #COVID19 in association with glucose-lowering drugs: a nationwide cohort study Read it here: https://t